Frontiers | Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 block...

www.frontiersin.org/journals/onc...

#Cancer #Kanser #BreastCancer #MemeKanseri #MedSky #OncSky #bcsm #enhertu #nerlynx #faslodex #taxol